ENDPOINTS NEWS1h
Novo­cure says elec­tric field ther­a­py ex­tends life for pan­cre­at­ic can­cer pa­tients by two months
Novocure announced Monday morning that its electrical field wearable device combined with chemotherapy passed a late-stage ...
ENDPOINTS NEWS1h
Ole­ma, No­var­tis ink an­oth­er agree­ment, this time for a late-stage breast can­cer tri­al
Olema Oncology and Novartis partner for Phase 3 trial combining palazestrant with Kisqali for breast cancer treatment. Olema ...
ENDPOINTS NEWS3h
Agenus launch­es bi­o­log­ics man­u­fac­tur­ing busi­ness to gen­er­ate cash
Agenus Bio is launching a CDMO arm using facilities in Berkeley and Emeryville, CA, while cutting spending to $100M by 2025.
ENDPOINTS NEWS5h
No­var­tis pays $1B up­front for PTC's Phase 2 Hunt­ing­ton's drug
Novartis is returning to Huntington's disease with a $1 billion upfront bet, plus another $1.9 billion in biobucks, for ...
ENDPOINTS NEWS6h
Apogee tar­gets Dupix­ent head-to-head next year as it out­lines broad pipeline plans
Apogee Therapeutics plans to challenge Sanofi and Regeneron's Dupixent with its lead drug APG777, an IL-13 targeting ...
ENDPOINTS NEWS5h
Merus drug shows ‘un­ex­pect­ed im­prove­ment’ in sec­ond-line head and neck can­cer study
Merus reported updated Phase 2 trial results for petosemtamab in head and neck cancer, showing 40.4% overall response rate ...